ArticleArchives of osteoporosis2025
Clinical impact of bisphosphonate treatment in reducing fragility fractures in Jordan: Insights from a developing country.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined whether bisphosphonate treatment can reduce fragility fractures in patients with osteoporosis in Jordan. We found significantly fewer fractures and better quality of life in treated patients, supporting the importance of early treatment in routine care settings.
introductionOsteoporosis is a major public health concern in aging populations, with fragility fractures contributing to significant morbidity, mortality, and healthcare burden. While bisphosphonates are widely used to reduce fracture risk, data from real-life clinical settings in the Middle East remain limited. This study aimed to evaluate the clinical outcomes associated with bisphosphonate therapy among osteoporotic patients in Jordan.
methodsWe conducted a retrospective, matched case-control study of 1,202 patients aged ≥ 50 years with confirmed osteoporosis across multiple hospitals in Jordan. Patients were grouped based on bisphosphonate treatment status. Clinical and functional outcomes-including fragility fractures, bone mineral density (BMD), FRAIL score, EQ-5D, and self-rated bone health-were compared between groups.
resultsOf 1,202 patients included, 604 received bisphosphonates and 598 did not. The bisphosphonate group had a significantly lower prevalence of fragility fractures (13.1% vs. 36.8%, p < 0.001) and multiple fractures (4.1% vs. 15.1%, p < 0.001). Mean lumbar spine and proximal femur BMD values were higher among treated patients (0.815 ± 0.090 g/cm
conclusionBisphosphonate therapy in routine clinical practice was associated with reduced fracture burden and better functional and quality of life outcomes among osteoporotic patients in Jordan. These results highlight the need for improved screening, timely treatment, and comprehensive osteoporosis care strategies in the region.
Indexed as
Identifiers
41222865What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.